|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,195.00 TWD | +5.29% |
|
+1.70% | +182.04% |
| 07-22 | PharmaEssentia Seeks Macau Nod to Expand Besremi Use for Rare Blood Cancer | MT |
| 07-09 | PharmaEssentia Swings to Profit in May as Revenue Balloons 108% | MT |
Company Valuation: PharmaEssentia Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 78,065 | 143,840 | 114,578 | 204,725 | 173,829 | 492,625 | - | - |
| Change | - | 84.26% | -20.34% | 78.68% | -15.09% | 183.4% | - | - |
| Enterprise Value (EV) 1 | 75,148 | 133,629 | 94,995 | 183,725 | 153,423 | 466,101 | 457,898 | 492,625 |
| Change | - | 77.82% | -28.91% | 93.4% | -16.49% | 203.8% | -1.76% | 7.58% |
| P/E | -27.1x | -98.6x | -179x | 69.3x | 34.6x | 45.9x | 33.4x | 27.3x |
| PBR | 19.1x | 11.2x | 4.79x | 7.45x | 5.46x | 11.8x | 9.16x | - |
| PEG | - | 1.8x | 3x | -0x | 0.5x | 0x | 0.9x | 1.2x |
| Capitalization / Revenue | 119x | 49.9x | 22.4x | 21x | 11.1x | 19.7x | 14.3x | 11.6x |
| EV / Revenue | 114x | 46.4x | 18.6x | 18.9x | 9.81x | 18.6x | 13.2x | 11.6x |
| EV / EBITDA | -29x | -74.2x | -57.8x | 87.3x | 28.8x | 47.9x | 31.3x | 29.7x |
| EV / EBIT | -26.6x | -65.9x | -49.6x | 106x | 31.1x | 43.9x | 28.7x | 30.3x |
| EV / FCF | -29.7x | -73.5x | -49.8x | 102x | 41.7x | 86.6x | 43.2x | - |
| FCF Yield | -3.37% | -1.36% | -2.01% | 0.98% | 2.4% | 1.15% | 2.32% | - |
| Dividend per Share 2 | - | - | - | 0.8936 | 1.352 | 0.9586 | 1.466 | - |
| Rate of return | - | - | - | 0.18% | 0.32% | 0.08% | 0.12% | - |
| EPS 2 | -8.773 | -3.932 | -1.568 | 7.214 | 12.25 | 26.04 | 35.81 | 43.81 |
| Distribution rate | - | - | - | 12.4% | 11% | 3.68% | 4.09% | - |
| Net sales 1 | 656.5 | 2,882 | 5,106 | 9,735 | 15,635 | 25,068 | 34,566 | 42,337 |
| EBITDA 1 | -2,595 | -1,800 | -1,645 | 2,104 | 5,327 | 9,735 | 14,635 | 16,591 |
| EBIT 1 | -2,822 | -2,028 | -1,913 | 1,736 | 4,928 | 10,612 | 15,940 | 16,243 |
| Net income 1 | -2,811 | -1,375 | -623.8 | 2,966 | 5,045 | 10,854 | 14,971 | 18,540 |
| Net Debt 1 | -2,917 | -10,211 | -19,582 | -21,000 | -20,406 | -26,524 | -34,728 | - |
| Reference price 2 | 238.02 | 387.49 | 281.07 | 499.59 | 423.70 | 1,195.00 | 1,195.00 | 1,195.00 |
| Nbr of stocks (in thousands) | 327,980 | 371,210 | 407,644 | 409,783 | 410,264 | 412,239 | - | - |
| Announcement Date | 02/03/22 | 01/03/23 | 27/02/24 | 26/02/25 | 03/03/26 | - | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 45.88x | 18.59x | 47.88x | 0.08% | 15.24B | |
| 33.11x | 8.21x | 25.31x | 0.04% | 56.19B | |
| 20.62x | 6.35x | 13.89x | 1.54% | 54.83B | |
| -18.25x | 4.33x | -7.59x | -.--% | 23.04B | |
| -41x | 13.02x | -38.35x | -.--% | 22.7B | |
| 25.46x | 4.98x | 13.19x | -.--% | 20.23B | |
| 24.92x | 4.83x | 15.71x | -.--% | 17.83B | |
| -786.44x | 37.38x | -4208.26x | -.--% | 15.65B | |
| 17.56x | 5.09x | 11.87x | -.--% | 14.03B | |
| -77.22x | 8.13x | -64.71x | -.--% | 12.71B | |
| Average | -75.54x | 11.09x | -419.11x | 0.17% | 25.24B | |
| Weighted average by Cap. | -38.61x | 9.65x | -253.96x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6446 Stock
- Valuation PharmaEssentia Corporation
Select your edition
All financial news and data tailored to specific country editions
